Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Capital Expenditures (2021 - 2023)

Aligos Therapeutics (ALGS) has disclosed Capital Expenditures for 3 consecutive years, with $7000.0 as the latest value for Q1 2023.

  • For the quarter ending Q1 2023, Capital Expenditures fell 98.64% year-over-year to $7000.0, compared with a TTM value of $435000.0 through Mar 2023, down 60.45%, and an annual FY2024 reading of $130000.0, up 584.21% over the prior year.
  • Capital Expenditures was $7000.0 for Q1 2023 at Aligos Therapeutics, down from $91000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $515000.0 in Q1 2022 and bottomed at $3000.0 in Q3 2022.
  • Average Capital Expenditures over 3 years is $204666.7, with a median of $152000.0 recorded in 2021.
  • The sharpest move saw Capital Expenditures surged 119.74% in 2022, then tumbled 98.64% in 2023.
  • Year by year, Capital Expenditures stood at $336000.0 in 2021, then tumbled by 72.92% to $91000.0 in 2022, then crashed by 92.31% to $7000.0 in 2023.
  • Business Quant data shows Capital Expenditures for ALGS at $7000.0 in Q1 2023, $91000.0 in Q4 2022, and $3000.0 in Q3 2022.